Role of therapeutic drug monitoring for protease inhibitors

Annals of Pharmacotherapy

Volumn 35, Issue 6, 2001, Pages 745-754

  John, Leela ^a   Marra, Fawziah ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Pharmacokinetics; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

CLINICAL TRIALS; DRUG MONITORING; DRUG RESISTANCE; DRUG SYNERGISM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0034995588     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10249     Document Type: Article

References (41)

1. Analysis of HIV clinical trials: Statistical magic?
2. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel
3. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV patients: A prospective cohort study. Swiss HIV Cohort Study
4. Outcome and predictors of failure in highly active antiretroviral therapy: One year follow-up of a cohort of human immunodeficiency type-1-infected persons
5. HIV protease inhibitors: Immunological insights
6. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
7. Resistance to anti-human immunodeficiency virus therapeutic agents
8. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
9. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
10. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC
11. Indinavir concentrations and antiviral effect
12. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
13. Virologic failure, resistance and plasma drug measurements in induction maintenance therapy trial (ARNS072, Trilege)
14. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
15. Indinavir pharmacokinetics and relationships between exposure and antiviral effect
16. Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy
17. Correlation between plasmatic levels of indinavir and immunologic and virologic parameters in HIV-patients
18. Independent benefit of sufficient drug levels and genotypic analysis in salvage therapy: Pharmacological data of the VIRADAPT study
19. HIV-1 protease inhibitor drug levels in treatment failure patients
20. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
21. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
22. HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications
23. Variability in trough plasma saquinavir concentrations in HIV patients - A case for therapeutic drug monitoring
24. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV infected individuals
25. Therapeutic drug monitoring in HIV-infected patients receiving indinavir
26. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps
27. Compliance to HIV-protease inhibitors (PIs) is more accurately measured by combining various methods including MEMS (electronic monitoring) and therapeutic drug monitoring
28. Therapeutic drug monitoring of nelfinavir in HIV-infected patients with liver disease
29. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection
30. Clinical pharmacokinetics in the 21st century: Does the evidence support definitive outcomes?
31. Carbamazepine-indinavir interaction causes antiretroviral therapy failure
32. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir and saquinavir in human plasma
33. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
34. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection
35. Simultaneous monitoring of five protease-inhibitors in HIV-infected patients by LC-tandem mass spectrometry
36. Pharmacokinetic evaluation of saquinavir soft gel capsules/ritonavir or SQV/NFV in combination with delavirdine and/or adefovir dipivoxil - ACTG 359
37. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
38. Human immunodeficiency virus drug resistance testing: State of the art in genotypic and phenotypic testing of antiretrovirals
39. Antiretroviral drug level monitoring: The next routine test in HIV management?